Logo image of TNGX

TANGO THERAPEUTICS INC (TNGX) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:TNGX - US87583X1090 - Common Stock

10.91 USD
+0.15 (+1.39%)
Last: 11/28/2025, 8:03:32 PM
10.92 USD
+0.01 (+0.09%)
After Hours: 11/28/2025, 8:03:32 PM
Fundamental Rating

4

TNGX gets a fundamental rating of 4 out of 10. The analysis compared the fundamentals against 533 industry peers in the Biotechnology industry. While TNGX has a great health rating, there are worries on its profitability. TNGX is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year TNGX has reported negative net income.
In the past year TNGX has reported a negative cash flow from operations.
TNGX had negative earnings in each of the past 5 years.
TNGX had a negative operating cash flow in each of the past 5 years.
TNGX Yearly Net Income VS EBIT VS OCF VS FCFTNGX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 -50M -100M

1.2 Ratios

TNGX has a Return On Assets of -47.83%. This is comparable to the rest of the industry: TNGX outperforms 52.16% of its industry peers.
Looking at the Return On Equity, with a value of -62.81%, TNGX is in the better half of the industry, outperforming 60.04% of the companies in the same industry.
Industry RankSector Rank
ROA -47.83%
ROE -62.81%
ROIC N/A
ROA(3y)-30.42%
ROA(5y)-20.6%
ROE(3y)-49.57%
ROE(5y)-33.14%
ROIC(3y)N/A
ROIC(5y)N/A
TNGX Yearly ROA, ROE, ROICTNGX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 -20 -40 -60

1.3 Margins

TNGX does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
TNGX Yearly Profit, Operating, Gross MarginsTNGX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 -100 -200 -300 -400

More info and screens

8

2. Health

2.1 Basic Checks

TNGX does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, TNGX has more shares outstanding
There is no outstanding debt for TNGX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
TNGX Yearly Shares OutstandingTNGX Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M
TNGX Yearly Total Debt VS Total AssetsTNGX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 2023 2024 100M 200M 300M 400M 500M

2.2 Solvency

An Altman-Z score of 13.00 indicates that TNGX is not in any danger for bankruptcy at the moment.
TNGX's Altman-Z score of 13.00 is amongst the best of the industry. TNGX outperforms 85.74% of its industry peers.
TNGX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 13
ROIC/WACCN/A
WACC8.64%
TNGX Yearly LT Debt VS Equity VS FCFTNGX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2020 2021 2022 2023 2024 0 100M -100M 200M 300M

2.3 Liquidity

TNGX has a Current Ratio of 8.88. This indicates that TNGX is financially healthy and has no problem in meeting its short term obligations.
TNGX has a better Current ratio (8.88) than 78.61% of its industry peers.
TNGX has a Quick Ratio of 8.88. This indicates that TNGX is financially healthy and has no problem in meeting its short term obligations.
TNGX has a better Quick ratio (8.88) than 78.61% of its industry peers.
Industry RankSector Rank
Current Ratio 8.88
Quick Ratio 8.88
TNGX Yearly Current Assets VS Current LiabilitesTNGX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 2023 2024 100M 200M 300M 400M

More info and screens

6

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 22.03% over the past year.
Looking at the last year, TNGX shows a very strong growth in Revenue. The Revenue has grown by 53.28%.
TNGX shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 4.34% yearly.
EPS 1Y (TTM)22.03%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%151.85%
Revenue 1Y (TTM)53.28%
Revenue growth 3Y4.34%
Revenue growth 5YN/A
Sales Q2Q%363.61%

3.2 Future

The Earnings Per Share is expected to grow by 10.06% on average over the next years. This is quite good.
Based on estimates for the next years, TNGX will show a very strong growth in Revenue. The Revenue will grow by 42.18% on average per year.
EPS Next Y8.28%
EPS Next 2Y-6.7%
EPS Next 3Y-6.47%
EPS Next 5Y10.06%
Revenue Next Year8.57%
Revenue Next 2Y-44.73%
Revenue Next 3Y-26.83%
Revenue Next 5Y42.18%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
TNGX Yearly Revenue VS EstimatesTNGX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 200M 400M 600M 800M 1B
TNGX Yearly EPS VS EstimatesTNGX Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 1 -1 2 3

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for TNGX. In the last year negative earnings were reported.
Also next year TNGX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
TNGX Price Earnings VS Forward Price EarningsTNGX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
TNGX Per share dataTNGX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1 -1

4.3 Compensation for Growth

TNGX's earnings are expected to decrease with -6.47% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-6.7%
EPS Next 3Y-6.47%

More info and screens

0

5. Dividend

5.1 Amount

TNGX does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

TANGO THERAPEUTICS INC

NASDAQ:TNGX (11/28/2025, 8:03:32 PM)

After market: 10.92 +0.01 (+0.09%)

10.91

+0.15 (+1.39%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-04 2025-11-04/bmo
Earnings (Next)02-25 2026-02-25/amc
Inst Owners108.56%
Inst Owner Change2.81%
Ins Owners1.53%
Ins Owner Change-9.04%
Market Cap1.47B
Revenue(TTM)66.50M
Net Income(TTM)-100.52M
Analysts86.67
Price Target12.5 (14.57%)
Short Float %28.1%
Short Ratio8.88
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)180.71%
Min EPS beat(2)1.36%
Max EPS beat(2)360.05%
EPS beat(4)2
Avg EPS beat(4)89.82%
Min EPS beat(4)-1.28%
Max EPS beat(4)360.05%
EPS beat(8)4
Avg EPS beat(8)49.54%
EPS beat(12)8
Avg EPS beat(12)40.29%
EPS beat(16)10
Avg EPS beat(16)31.6%
Revenue beat(2)1
Avg Revenue beat(2)-5.63%
Min Revenue beat(2)-53.3%
Max Revenue beat(2)42.04%
Revenue beat(4)1
Avg Revenue beat(4)-20.08%
Min Revenue beat(4)-53.3%
Max Revenue beat(4)42.04%
Revenue beat(8)3
Avg Revenue beat(8)10.95%
Revenue beat(12)5
Avg Revenue beat(12)18.27%
Revenue beat(16)6
Avg Revenue beat(16)14.08%
PT rev (1m)12.64%
PT rev (3m)12.83%
EPS NQ rev (1m)7.37%
EPS NQ rev (3m)6.16%
EPS NY rev (1m)0.95%
EPS NY rev (3m)6.77%
Revenue NQ rev (1m)-44.93%
Revenue NQ rev (3m)-78.16%
Revenue NY rev (1m)-0.01%
Revenue NY rev (3m)13%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 22.08
P/FCF N/A
P/OCF N/A
P/B 9.18
P/tB 9.18
EV/EBITDA N/A
EPS(TTM)-0.92
EYN/A
EPS(NY)-1.38
Fwd EYN/A
FCF(TTM)-1.09
FCFYN/A
OCF(TTM)-1.08
OCFYN/A
SpS0.49
BVpS1.19
TBVpS1.19
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -47.83%
ROE -62.81%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-30.42%
ROA(5y)-20.6%
ROE(3y)-49.57%
ROE(5y)-33.14%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.32
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 39.22%
Cap/Sales 1.43%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 8.88
Quick Ratio 8.88
Altman-Z 13
F-Score4
WACC8.64%
ROIC/WACCN/A
Cap/Depr(3y)190.33%
Cap/Depr(5y)N/A
Cap/Sales(3y)12.3%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)22.03%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%151.85%
EPS Next Y8.28%
EPS Next 2Y-6.7%
EPS Next 3Y-6.47%
EPS Next 5Y10.06%
Revenue 1Y (TTM)53.28%
Revenue growth 3Y4.34%
Revenue growth 5YN/A
Sales Q2Q%363.61%
Revenue Next Year8.57%
Revenue Next 2Y-44.73%
Revenue Next 3Y-26.83%
Revenue Next 5Y42.18%
EBIT growth 1Y21.13%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-20.03%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-21.16%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-22.75%
OCF growth 3YN/A
OCF growth 5YN/A

TANGO THERAPEUTICS INC / TNGX FAQ

What is the ChartMill fundamental rating of TANGO THERAPEUTICS INC (TNGX) stock?

ChartMill assigns a fundamental rating of 4 / 10 to TNGX.


What is the valuation status for TNGX stock?

ChartMill assigns a valuation rating of 0 / 10 to TANGO THERAPEUTICS INC (TNGX). This can be considered as Overvalued.


What is the profitability of TNGX stock?

TANGO THERAPEUTICS INC (TNGX) has a profitability rating of 1 / 10.


Can you provide the financial health for TNGX stock?

The financial health rating of TANGO THERAPEUTICS INC (TNGX) is 8 / 10.


Can you provide the expected EPS growth for TNGX stock?

The Earnings per Share (EPS) of TANGO THERAPEUTICS INC (TNGX) is expected to grow by 8.28% in the next year.